Other OTC - Delayed Quote USD

Genmab A/S (GNMSF)

269.87

-9.73

(-3.48%)

At close: April 25 at 3:34 PM EDT

Transactions in Connection with Share Buy-back Program Genmab

Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from April 15, 2024 to April 19, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announ

GlobeNewswire 3 days ago

GMAB

GNMSF
-3.48%
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024

Company Announcement Net sales of DARZALEX® in the first quarter of 2024 totaled USD 2,692 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; April 16, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson we

GlobeNewswire 9 days ago

GMAB

GNMSF
-3.48%
Roche reports survival data for new dual-acting lymphoma drug

The results could give Roche’s Columvi an edge over a rival medicine from AbbVie and Genmab, while Regeneron awaits an approval of its own therapy.

BioPharma Dive 10 days ago

ROG.SW

ABBV

GMAB.CO
Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; April 8, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from April 1, 2024 to April 5, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcem

GlobeNewswire 17 days ago

GMAB

GNMSF
-3.48%
Genmab Takes The Next Step In Its 'Evolution' With A $1.8 Billion Takeover

Genmab stock slumped Wednesday after the Danish biotech announced it will buy privately held ProfoundBio for $1.8 billion.

Investor's Business Daily 22 days ago

GMAB
Stocks to Watch Wednesday: Disney, Intel, Tesla, Trump Media

**Walt Disney (DIS)**: The entertainment giant's shareholder meeting was due to start at 1 p.m. ET. Activist hedge-fund firm Trian Partners is waging a proxy fight with Disney. Its shares edged lower.

The Wall Street Journal 22 days ago

DIS

PARA

PARAA
Genmab buys ProfoundBio for $1.8B, adding to ADC dealmaking flurry

The buyout continues a surge in M&A for developers of antibody-drug conjugates and gives Genmab a potential competitor to a medicine AbbVie recently purchased in a multibillion-dollar acquisition.

BioPharma Dive 22 days ago

GMAB
Genmab Strengthens Oncology Portfolio With $1.8 Bln Acquisition of ProfoundBio

Danish biotech Genmab will buy U.S.-based ProfoundBio for $1.8 billion in cash as it looks to bolster its pipeline of cancer treatments.

The Wall Street Journal 22 days ago

GMAB

GNMSF
-3.48%
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

COPENHAGEN, Denmark & SEATTLE, April 03, 2024--Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. announced today that the companies have entered into a definitive agreement for Genmab to acquire ProfoundBio in an all-cash transaction. ProfoundBio is a privately-owned clinical-stage biotechnology company developing next-generation ADCs and ADC technologies for the treatment of certain cancers, including ovarian cancer and other FRα-expressing solid tumors. Genmab will acquire ProfoundBio for USD 1.

Business Wire 22 days ago

GMAB

GNMSF
-3.48%
Completion of share buy-back program

Company Announcement COPENHAGEN, Denmark; March 18, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 15, 2024 On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share buy-back program was expected to be completed no later than March 15, 2024, and comprised up to 190,000 shares. The following transactions were executed under the program from M

GlobeNewswire last month

GMAB

GNMSF
-3.48%
30 Biggest Biotechnology Companies in the World

In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]

Insider Monkey last month

ILMN

AZN

EXEL
Genmab Announces Initiation of Share Buy-Back Program

Company Announcement Repurchase of up to DKK 3.5 billion worth of sharesCompletion expected no later than December 16, 2024 COPENHAGEN, Denmark; March 15, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program. The share buy-back program will be undertaken on the terms set out below and in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Time fra

GlobeNewswire last month

GMAB

GNMSF
-3.48%
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; March 13, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Gen

GlobeNewswire last month

GMAB

GNMSF
-3.48%
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; March 13, 2024 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 13, 2024, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant 12,847 restricted stock units to members of the Board of Directors and employees of the Company and the Company’s subsidiaries and 6,660 warrants to the employees o

GlobeNewswire last month

GMAB

GNMSF
-3.48%
Passing of Genmab A/S’ Annual General Meeting

Company Announcement At Genmab A/S’ Annual General Meeting held today March 13, 2024, the Annual Report for 2023 was approvedDischarge was given to the Board of Directors and the Executive Management and the year’s profit was carried forwardThe 2023 Compensation Report was approvedSix members of the Board of Directors were re-electedDeloitte was elected as the new auditor of the CompanyThe proposal from the Board of Directors on the Board of Directors' remuneration for 2024, the proposal to adop

GlobeNewswire last month

GMAB

GNMSF
-3.48%
Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; February 27, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 48,429 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 7,325 shares at DKK 1,025.00,19,631 shares at DKK 1,032.00,2,473 shares at DKK 1,050.00,1,422 shares at DKK 1,

GlobeNewswire last month

GMAB

GNMSF
-3.48%
$U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma$
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

COPENHAGEN, Denmark, February 27, 2024--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy.

Business Wire last month

GMAB

GNMSF
-3.48%
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; February 23, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 418,646 restricted stock units to members of management and employees of the company as well as the company's subsidiaries and 316,899 warrants to employees of the company and the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The vesti

GlobeNewswire 2 months ago

GMAB

GNMSF
-3.48%
Genmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call Transcript

Genmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call Transcript February 14, 2024 Genmab A/S misses on earnings expectations. Reported EPS is $0.14 EPS, expectations were $0.35. Genmab A/S isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you […]

Insider Monkey 2 months ago

GMAB.CO
Genmab: Growth Is Still a Better Choice

A closer look at one of the leaders in the development of anti-cancer drugs

GuruFocus.com 2 months ago

GMAB.CO

Performance Overview

Return	GNMSF	OMX Copenhagen 25 Index
YTD	-14.52%	+3.54%
1-Year	-34.45%	+2.44%
3-Year	-27.05%	+7.05%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Genmab A/S (GNMSF)

Transactions in Connection with Share Buy-back Program Genmab

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024

Roche reports survival data for new dual-acting lymphoma drug

Transactions in Connection with Share Buy-back Program

Genmab Takes The Next Step In Its 'Evolution' With A $1.8 Billion Takeover

Stocks to Watch Wednesday: Disney, Intel, Tesla, Trump Media

Genmab buys ProfoundBio for $1.8B, adding to ADC dealmaking flurry

Genmab Strengthens Oncology Portfolio With $1.8 Bln Acquisition of ProfoundBio

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

Completion of share buy-back program

30 Biggest Biotechnology Companies in the World

Genmab Announces Initiation of Share Buy-Back Program

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Passing of Genmab A/S’ Annual General Meeting

Capital Increase in Genmab as a Result of Employee Warrant Exercise

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Genmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call Transcript

Genmab: Growth Is Still a Better Choice

Performance Overview